Covaxin’s US approval delayed over data, Bharat Biotech’s partner to file for full approval
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 22, 2022
SUNDAY, MAY 22, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Covaxin’s US approval delayed over data, Bharat Biotech’s partner to file for full approval

Coronavirus chronicle

Hindustan Times
11 June, 2021, 01:10 pm
Last modified: 11 June, 2021, 01:13 pm

Related News

  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • WHO issues emergency use listing for COVAXIN Covid-19 jab
  • India recommends homemade Covid-19 vaccine for kids aged 2 and above
  • India to miss end-July vaccination target as Bharat Biotech lags
  • India's Bharat Biotech says regulatory steps taken for Brazil vaccine contract

Covaxin’s US approval delayed over data, Bharat Biotech’s partner to file for full approval

Ocugen, which has partnered with Bharat Biotech to produce Covaxin for US market, said it will now seek full approval for the shot

Hindustan Times
11 June, 2021, 01:10 pm
Last modified: 11 June, 2021, 01:13 pm
Photo: UNB
Photo: UNB

Bharat Biotech's partner for Covaxin in the US has said it will no longer seek an emergency use authorisation for its Covid-19 vaccine candidate and will file for a full approval of the shot after the Food and Drug Administration (FDA) asked for additional information and data. Ocugen, which has partnered with Bharat Biotech to produce Covaxin for the US market, said the decision was based on a recommendation from the country's top public health regulator.

"The FDA provided feedback to Ocugen regarding the Master File submitted previously and recommended that we pursue a BLA submission instead of an EUA application for the vaccine candidate and requested additional information and data," Ocugen, which has partnered with Bharat Biotech to produce Covaxin for the US market, said in a statement to the New York Stock Exchange (NYSE).

As a result of this, Ocugen said, it would no longer pursue a EUA application and would instead aim to file for full approval of the shot and go for a Biological License Application (BLA)—the full approval for a vaccine shot. The firm added that it expects data from an additional clinical trial to be required for a full-use application.

"While this will extend our timelines, we're committed to bringing Covaxin to the US," Ocugen chief executive officer (CEO) Dr Shankar Musunuri said. In addition to the US, Ocugen has secured exclusive rights to market the vaccine in Canada as well and is in discussion with Health Canada for regulatory approval.

Covaxin is India's only homemade vaccine against the coronavirus disease and one among three to have been approved for use; Covishield and Sputnik V are the other two shots. Of these, Covaxin and Covishield have been used since India began its vaccination drive on January 16.

The shot was found to be 78% effective against the symptomatic disease, and 100% protection from serious illness, according to the interim analysis. Bharat Biotech was to announce the results of phase three clinical trials in June but said on June 10 it would do so only a month later, in July.

Bharat Biotech Covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Project delays: The Sinohydro style 
    Project delays: The Sinohydro style 
  • Photo: TBS
    37,000 BO account holders sell all shares in 11 days
  • Photo: Reuters
    Monkeypox: Govt puts ports on alert 

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap
  • Photo: BSS/AFP
    Covax calls for urgent action to close vaccine equity gap
  • Photo: Collected
    Thousands of Covid-negative Beijing residents sent to quarantine
  • A man checks phone at Lujiazui financial district in Pudong, Shanghai, China March 14, 2019. Photo :Reuters
    Shanghai inches towards Covid lockdown exit, Beijing plays defence
  • North Korean leader Kim Jong Un delivers opening remarks during the 2nd Conference of Secretaries of Primary Committees of the Workers' Party of Korea (WPK), in this photo released on February 27, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS/File Photo
    N Korea reports over 200,000 fever cases for 5th day amid Covid wave

Related News

  • India gives nod to Bharat Biotech for intranasal Covid booster doses
  • WHO issues emergency use listing for COVAXIN Covid-19 jab
  • India recommends homemade Covid-19 vaccine for kids aged 2 and above
  • India to miss end-July vaccination target as Bharat Biotech lags
  • India's Bharat Biotech says regulatory steps taken for Brazil vaccine contract

Features

The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters

Eco-fascism: The greenwashing of the far right

13h | Panorama
Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque

Green-backed Heron: Nothing but a prayer to catch a fish  

15h | Panorama
Illustration: TBS

‘High logistics cost weakens Bangladesh’s competitiveness’

17h | Panorama
Every morning is a new beginning for all

Seashore

17h | In Focus

More Videos from TBS

Wheat prices double in India

Wheat prices double in India

6h | Videos
Is Washington-Moscow agreement possible?

Is Washington-Moscow agreement possible?

7h | Videos
Pigeon exhibition for the first time in Gazipur

Pigeon exhibition for the first time in Gazipur

11h | Videos
Photo: TBS

US Congress to hold first public UFO panel

13h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab